Connor, Clark & Lunn Investment Management (CC&L)’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $381K | Sell |
274,431
-479,475
| -64% | -$659K | ﹤0.01% | 1361 |
|
|
2025
Q4 | $1.21M | Sell |
753,906
-266,762
| -26% | -$559K | ﹤0.01% | 1074 |
|
|
2025
Q3 | $2.79M | Sell |
1,020,668
-160,091
| -14% | -$533K | 0.01% | 749 |
|
|
2025
Q2 | $4.3M | Buy |
1,180,759
+210,925
| +22% | +$580K | 0.02% | 623 |
|
|
2025
Q1 | $1.86M | Sell |
969,834
-57,062
| -6% | -$116K | 0.01% | 753 |
|
|
2024
Q4 | $1.95M | Sell |
1,026,896
-19,795
| -2% | -$34.4K | 0.01% | 733 |
|
|
2024
Q3 | $1.38M | Buy |
1,046,691
+632
| +0.1% | +$844 | 0.01% | 779 |
|
|
2024
Q2 | $1.07M | Buy |
1,046,059
+1,588
| +0.2% | +$1.96K | ﹤0.01% | 830 |
|
|
2024
Q1 | $1.91M | Buy |
1,044,471
+424,152
| +68% | +$678K | 0.01% | 685 |
|
|
2023
Q4 | $769K | Sell |
620,319
-3,823
| -0.6% | -$3.9K | ﹤0.01% | 936 |
|
|
2023
Q3 | $712K | Buy |
624,142
+9,264
| +2% | +$11.9K | ﹤0.01% | 931 |
|
|
2023
Q2 | $563K | Buy |
614,878
+311,901
| +103% | +$301K | ﹤0.01% | 959 |
|
|
2023
Q1 | $170K | Buy |
302,977
+182,924
| +152% | +$140K | ﹤0.01% | 1114 |
|
|
2022
Q4 | $69.3K | Sell |
120,053
-390,049
| -76% | -$122K | ﹤0.01% | 1134 |
|
|
2022
Q3 | $161K | Buy |
510,102
+283,332
| +125% | +$111K | ﹤0.01% | 1011 |
|
|
2022
Q2 | $80K | Sell |
226,770
-244,911
| -52% | -$103K | ﹤0.01% | 995 |
|
|
2022
Q1 | $339K | Buy |
471,681
+69,265
| +17% | +$148K | ﹤0.01% | 849 |
|
|
2021
Q4 | $909K | Sell |
402,416
-28,255
| -7% | -$77K | ﹤0.01% | 694 |
|
|
2021
Q3 | $1.24M | Buy |
430,671
+219,381
| +104% | +$626K | 0.01% | 603 |
|
|
2021
Q2 | $801K | Buy |
211,290
+120,633
| +133% | +$406K | ﹤0.01% | 704 |
|
|
2021
Q1 | $307K | Buy |
+90,657
| New | +$327K | ﹤0.01% | 860 |
|
|
2017
Q4 | – | Sell |
-13,755
| Closed | -$271K | – | 770 |
|
|
2017
Q3 | $271K | Sell |
13,755
-30,045
| -69% | -$462K | ﹤0.01% | 716 |
|
|
2017
Q2 | $629K | Buy |
+43,800
| New | +$555K | ﹤0.01% | 564 |
|
|
2016
Q3 | – | Sell |
-16,100
| Closed | -$120K | – | 832 |
|
|
2016
Q2 | $120K | Sell |
16,100
-52,100
| -76% | -$455K | ﹤0.01% | 788 |
|
|
2016
Q1 | $614K | Sell |
68,200
-29,725
| -30% | -$241K | ﹤0.01% | 537 |
|
|
2015
Q4 | $1.26M | Buy |
97,925
+8,500
| +10% | +$86.7K | 0.01% | 409 |
|
|
2015
Q3 | $864K | Buy |
89,425
+52,525
| +142% | +$482K | 0.01% | 432 |
|
|
2015
Q2 | $380K | Buy |
36,900
+13,000
| +54% | +$111K | ﹤0.01% | 465 |
|
|
2015
Q1 | $266K | Buy |
23,900
+10,200
| +74% | +$109K | ﹤0.01% | 470 |
|
|
2014
Q4 | $159K | Buy |
+13,700
| New | +$196K | ﹤0.01% | 539 |
|
Other funds holding AKBA
VCM
VPM